Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (-R): A phase 2 clinical and correlative study Meeting Abstract

  

Authors:	Kazandjian, D.; Hill, E.; Morrison, C.; Dew, A.; Korde, N.; Mailankody, S.; Manasanch, E. E.; Kwok, M. L.; Bhutani, M.; Tageja, N.; Zhang, Y.; Carpenter, A.; Epstein, M.; Emanuel, M.; Lu, C.; Braylan, R. C.; Calvo, K. R.; Choyke, P.; Dulau-Florea, A.; Mena, E.; Lindenberg, L.; Maric, I.; Patel, N.; Stetler-Stevenson, M.; Wang, H. W.; Yuan, C. M.; Steinberg, S. M.; Figg, W. D.; Roschewski, M.; Landgren, O.
Abstract Title:	Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (-R): A phase 2 clinical and correlative study
Meeting Title:	62nd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	136
Issue:	Suppl. 1
Meeting Dates:	2020 Dec 5-8
Meeting Location:	Virtual
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2020-11-05
Language:	English
ACCESSION:	WOS:000607547203027
DOI:	10.1182/blood-2020-136148
PROVIDER:	wos
Notes:	Meeting Abstract; 43 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/197776